|
|
|
|
|
|
Sponsors and Collaborators: |
Ireland Cancer Center National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00006255 |
RATIONALE: Radiofrequency ablation uses high-frequency electric current to heat and kill tumor cells. Magnetic resonance imaging-guided radiofrequency ablation may an effective treatment for primary kidney cancer, liver metastases, or other solid tumors.
PURPOSE: Phase II trial to study the effectiveness of magnetic-resonance-guided radiofrequency ablation in treating patients who have primary kidney cancer, liver metastases, or other solid tumors.
Condition | Intervention | Phase |
Kidney Cancer Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific |
Procedure: radiofrequency ablation Procedure: thermal ablation therapy |
Phase II |
MedlinePlus related topics: | Cancer Kidney Cancer |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II Study of Magnetic Resonance Guided and Monitored Interstitial Thermal Radiofrequency Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases |
Study Start Date: | April 2000 |
OBJECTIVES:
OUTLINE: Patients are stratified according to disease (localized hepatic metastases vs primary renal neoplasms vs solid tumors in other sites).
Patients undergo thermal ablation by radiofrequency energy under magnetic resonance guidance. Thermal ablation continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures.
Patients are followed at 2 weeks and at 3, 6, 9, and 12 months.
PROJECTED ACCRUAL: A total of 28-39 patients will be accrued for this study within 22-36 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of primary renal cell carcinoma, hepatic metastases, or other solid tumor meeting the following criteria:
No more than 5 measurable metastatic masses in the liver
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, Ohio | |||||
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University | |||||
Cleveland, Ohio, United States, 44106-5056 |
Ireland Cancer Center |
National Cancer Institute (NCI) |
Study Chair: | John R. Haaga, MD | Ireland Cancer Center |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000068188, CWRU-2Y00, NCI-G00-1850 |
First Received: | September 11, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00006255 |
Health Authority: | United States: Federal Government |
|
|
|
|